 |
 |
> Dear allstaters, > > please find attached the latest contract vacancy for you to review; > > TITLE: Project Statistician - Phase III-IV Anti-Infectives Trials > > ROLE: Essential, M.Sc/B.Sc/Phd in statistics, biostatistics or related > subject, 3yrs+ minimum pharmaceutical/CRO experience, minimum 3yrs+ > statistics experience, SAS programming (v6.12), SAS/base, SAS/macro & some > phase II-III study experience. Desirable, dose justification analysis, > logistic regression, exploratory analysis, submission project experience & > any specific therapeutic knowledge in > anti-fungal/anti-viral/anti-bacterial/anti-infectives. Working for this > worldwide pharmaceutical giant on their worldwide phase III-IV study, your > duties will include; preparing/writing analysis plans for submission, > implementing the statistical analysis plans, SAS programming (v6.12 on > Unix), exploratory analysis & dose justification analysis. Accomodation is > provided with this role and is not deducted from your rate. This is an > exclusive role for a start when you are available, interview times await > for an immediate decision. > > LOCATION: Germany > CONTRACT LENGTH: 6 months - 12 months > RATE: Dependant on experience > START DATE: ASAP, but they will wait for notice periods > > If you interested in this role please feel free to contact me for further > details at the earliest possible moment. > > Regards > > James Carrera > European Contracts Manager > Pharmaceutical, Healthcare & CRO division. > 1st IT People > Tel: +44 (0) 207 940 3900 > Fax: +44 (0) 207 886 8161 > mailto:[log in to unmask] > www.1st-itpeople.com > > Offices in UK, Switzerland, The Netherlands & Hong Kong > This email is confidential and intended solely for the use of the > individual to whom it is addressed. Any views or opinions presented are > solely those of the author and do not represent those of the company from > which the email was sent. If you are not the intended recipient, be > advised that you have received this e-mail in error and that any use, > dissemination forwarding, printing or copying of this e-mail is strictly > prohibited. While every effort has been made to scan this e-mail, we can > not accept any responsibility for loss of business or damage caused > arising from this e-mail. >